NATURAL PRODUCT FROM GELATINOUS ZOOPLANKTON

来自凝胶状浮游动物的天然产品

• 批准号: 3493200
• 负责人: JANICE L THOMPSON
• 金额: $ 5万
• 依托单位: CALBIOMARINE TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-07-12 至 1993-04-11
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3493200
• 关键词: Cnidaria; Invertebrata; Mollusca; Tunicata; antineoplastics; biological products; chromatography; clone cells; cytotoxicity; drug screening /evaluation; marine biology; mass spectrometry; neoplastic cell; nuclear magnetic resonance spectroscopy; solvent extraction

The goal of this project is to systematically explore the gelatinous zooplankton for antitumor and other biological activities. The following invertebrate groups will be collected: Cnidaria (hydromedusae, hydroids, scyphomedusae, siphonophores), Ctenophora, Mollusca (pteropods, heteropods, nudibranchs), and Urochordata (tunicates, doliolids, pyrosomes). Phase I will concentrate on collecting 10% of a systematic program total of 150-200 species and on evaluating the cost-effectiveness of several collection and recollection methods (bucket, trawl, and SCUBA). Samples will be extracted and screened against a panel of 5-6 human tumor cell lines. Active extracts will be further fractionated according to biological activity, and described chemically. Phase II will continue this work and the NCI will be given the opportunity to screen the collection. It is expected that new chemical entities, with important pharmaceutical activities, will be described and patented; they will be licensed to the government or pharmaceutical companies for development. The evaluation of gelatinous zooplankton represents a new opportunity for drug discovery. Only a few species have been evaluated due to the perceived technical difficulty of collecting and recollecting zooplankton in kilogram quantities. These planktonic species are likely sources of bioactive metabolites since their benthic (bottom-living) relatives have yielded many bioactive metabolites.

该项目的目的是系统地探索凝胶状 用于抗肿瘤和其他生物活性的浮游动物。 下列 将收集无脊椎动物组：cnidaria（Hydromedusae，Hydroids， Scyphomedusae，siphonophores），ctenophora，Mollusca（翼足，异脚类，杂动， 裸子）和urochordata（束缚，doliolids，焦油体）。 第一阶段 将集中精力收集150-200的系统计划的10％ 物种和评估几个集合的成本效益和 回忆方法（铲斗，拖网和水肺）。 样本将是 萃取并筛选为5-6个人类肿瘤细胞系的面板。 活性提取物将根据生物学进一步分级 活性，化学描述。 第二阶段将继续这项工作， NCI将有机会筛选该系列。 这是 期望具有重要药物的新化学实体 活动将被描述和专利；他们将获得许可 政府或制药公司开发。 凝胶状浮游生物的评估代表了一个新的机会 药物发现。 由于 感知到收集和回忆浮游生物的技术困难 以公斤数量。 这些浮游物种可能是 生物活性代谢物以来，他们的底栖（底生）亲属具有 产生了许多生物活性代谢产物。